Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;60(9):1167-1174.
doi: 10.1007/s00120-021-01535-3. Epub 2021 May 27.

[Systemic treatment of bladder cancer]

[Article in German]
M Haas  1 , M Burger  2 , M J Schnabel  2
Affiliations
Review

[Systemic treatment of bladder cancer]

[Article in German]
M Haas et al. Urologe A. 2021 Sep.

Abstract
in English, German

Cisplatin-based chemotherapy regimens represent the standard of care in patients with locally advanced or metastatic urothelial carcinoma of the bladder. However, many patients are ineligible for cisplatin due to comorbidities or performance status. Immunotherapy with checkpoint inhibitors (CPI) has become a well-established treatment alternative in metastatic bladder cancer. The following review discusses current literature and guideline recommendations based on two case studies, in order to provide practical know-how about therapy sequences and treatment processes.

Die Cisplatin-basierte Polychemotherapie stellt in der Systemtherapie des muskelinvasiven Harnblasenkarzinoms („muscle-invasive bladder cancer“, MIBC) seit langer Zeit den Therapiestandard dar. In den vergangenen Jahren haben sich zudem auch Immun-Checkpoint-Inhibitoren (ICI) als Therapiealternative bei Cisplatin-ungeeigneten Patienten und in der Therapiesequenz des metastasierten Urothelkarzinoms etabliert. In diesem Artikel sollen die verfügbare Literatur und aktuelle Leitlinien anhand von zwei Patientenbeispielen aufgearbeitet werden, um so Therapieentscheidungen und Behandlungspfade in der Systemtherapie des lokal begrenzten und metastasierten Urothelkarzinoms der Harnblase aufzuzeigen und praxisrelevante Inhalte zu vermitteln.

Keywords: Immune checkpoint inhibitors; Neoplasm metastasis; Polychemotherapy; Programmed cell death ligand 1; Resektion, transurethral.

PubMed Disclaimer

References

Literatur

    1. Gesellschaft der epidemiologischen Krebsregister in Deutschland (2021) Atlas der Krebsinzidenz und -mortalität in Deutschland (GEKID-Atlas). https://atlas.gekid.de/CurrentVersion/atlas.html . Zugegriffen: 21. Febr. 2021
    1. Stenzl A, Penkoff H, Dajc-Sommerer E et al (2011) Detection and clinical outcome of urinary bladder cancer with 5‑aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial. Cancer 117(5):938–947. https://doi.org/10.1002/cncr.25523 - DOI - PubMed
    1. Geavlete B, Multescu R, Georgescu D et al (2012) Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: Does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int 109(4):549–556. https://doi.org/10.1111/j.1464-410X.2011.10374.x - DOI - PubMed
    1. Mowatt G, N’Dow J, Vale L et al (2011) Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis. Int J Technol Assess Health Care 27(1):3–10. https://doi.org/10.1017/S0266462310001364 - DOI - PubMed
    1. Kausch I, Sommerauer M, Montorsi F et al (2010) Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 57(4):595–606. https://doi.org/10.1016/j.eururo.2009.11.041 - DOI - PubMed

LinkOut - more resources